Corient Private Wealth
ESPR

Corient Private Wealth’s Esperion Therapeutics ESPR Stock Holding History

Corient Private Wealth’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,821
Closed -$13.8K – 3107
2026
Q1 		$13.8K Buy
+11,821
New +$37.4K ﹤0.01% 2796
2025
Q2 		– Sell
-15,000
Closed -$21.6K – 2471
2025
Q1 		$21.6K Sell
15,000
-35,745
-70% -$65.9K ﹤0.01% 2254
2024
Q4 		$112K Sell
50,745
-108,702
-68% -$254K ﹤0.01% 2209
2024
Q3 		$263K Sell
159,447
-23,053
-13% -$46.5K ﹤0.01% 2070
2024
Q2 		$405K Buy
+182,500
New +$429K ﹤0.01% 1757
2023
Q2 		– Sell
-17,334
Closed -$27.6K – 2101
2023
Q1 		$27.6K Buy
+17,334
New +$89.5K ﹤0.01% 1964

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Corient Private Wealth's ESPR Position: Q2 2026 in Review

Corient Private Wealth sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 11,821 shares — an estimated $13.8K sold.

Corient Private Wealth first reported a position in ESPR in Q1 2023 and held it in 6 quarters. The position peaked at $405K in Q2 2024. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Corient Private Wealth reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Corient Private Wealth sold 11,821 Esperion Therapeutics shares in Q2 2026, an estimated $13.8K.
  • Corient Private Wealth first reported a position in Esperion Therapeutics in Q1 2023 and held it in 6 quarters.
  • Corient Private Wealth's Esperion Therapeutics position peaked at $405K in Q2 2024.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.